FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:20-28 January 6, 2005 Number 1 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Ehrenstein, M. R. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Statins lower the levels of low-density lipoprotein (LDL) cholesterol and C-reactive protein (CRP). Whether this latter property affects clinical outcomes is unknown.

Methods We evaluated relationships between the LDL cholesterol and CRP levels achieved after treatment with 80 mg of atorvastatin or 40 mg of pravastatin per day and the risk of recurrent myocardial infarction or death from coronary causes among 3745 patients with acute coronary syndromes.

Results Patients in whom statin therapy resulted in LDL cholesterol levels of less than 70 mg per deciliter (1.8 mmol per liter) had lower event rates than those with higher levels (2.7 vs. 4.0 events per 100 person-years, P=0.008). However, a virtually identical difference was observed between those who had CRP levels of less than 2 mg per liter after statin therapy and those who had higher levels (2.8 vs. 3.9 events per 100 person-years, P=0.006), an effect present at all levels of LDL cholesterol achieved. For patients with post-treatment LDL cholesterol levels of more than 70 mg per deciliter, the rates of recurrent events were 4.6 per 100 person-years among those with CRP levels of more than 2 mg per liter and 3.2 events per 100 person-years among those with CRP levels of less than 2 mg per liter; the respective rates among those with LDL cholesterol levels of less than 70 mg per deciliter were 3.1 and 2.4 events per 100 person-years (P<0.001). Although atorvastatin was more likely than pravastatin to result in low levels of LDL cholesterol and CRP, meeting these targets was more important in determining the outcomes than was the specific choice of therapy. Patients who had LDL cholesterol levels of less than 70 mg per deciliter and CRP levels of less than 1 mg per liter after statin therapy had the lowest rate of recurrent events (1.9 per 100 person-years).

Conclusions Patients who have low CRP levels after statin therapy have better clinical outcomes than those with higher CRP levels, regardless of the resultant level of LDL cholesterol. Strategies to lower cardiovascular risk with statins should include monitoring CRP as well as cholesterol.

Source Information

From the Center for Cardiovascular Disease Prevention (P.M.R., N.R., L.M.R.), the Donald W. Reynolds Center for Cardiovascular Research (P.M.R., D.M., N.R.), and the Thrombolysis in Myocardial Infarction Study Group (C.P.C., D.M., C.H.M., M.A.P., E.B.), Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston.

Address reprint requests to Dr. Ridker at the Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, 900 Commonwealth Ave. East, Boston, MA 02215, or at pridker{at}partners.org.

Full Text of this Article

Related Letters:

C-Reactive Protein Levels and Outcomes after Statin Therapy
Cohen B., Singh D., Greenland P., Lloyd-Jones D. M., Moss A. J., Jaber B. L., Madias N. E., Ridker P. M, Cannon C. P., Braunwald E.
Extract | Full Text | PDF  
N Engl J Med 2005; 352:1603-1605, Apr 14, 2005. Correspondence

This article has been cited by other articles:

• Yasue, H., Mizuno, Y., Harada, E., Itoh, T., Nakagawa, H., Nakayama, M., Ogawa, H., Tayama, S., Honda, T., Hokimoto, S., Ohshima, S., Hokamura, Y., Kugiyama, K., Horie, M., Yoshimura, M., Harada, M., Uemura, S., Saito, Y., for the SCAST (Statin and Coronary Artery Spasm Tr, (2008). Effects of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, fluvastatin, on coronary spasm after withdrawal of calcium-channel blockers.. J Am Coll Cardiol 51: 1742-1748 [Abstract] [Full Text]  
• Kolz, M., Koenig, W., Muller, M., Andreani, M., Greven, S., Illig, T., Khuseyinova, N., Panagiotakos, D., Pershagen, G., Salomaa, V., Sunyer, J., Peters, A., for the AIRGENE Study Group, (2008). DNA variants, plasma levels and variability of C-reactive protein in myocardial infarction survivors: results from the AIRGENE study. Eur Heart J 29: 1250-1258 [Abstract] [Full Text]  
• Lund, S. S, Tarnow, L., Stehouwer, C. D A, Schalkwijk, C. G, Teerlink, T., Gram, J., Winther, K., Frandsen, M., Smidt, U. M, Pedersen, O., Parving, H.-H., Vaag, A. A (2008). Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. Eur J Endocrinol 158: 631-641 [Abstract] [Full Text]  
• Shen, J., Arnett, D. K., Parnell, L. D., Peacock, J. M., Lai, C.-Q., Hixson, J. E., Tsai, M. Y., Province, M. A., Straka, R. J., Ordovas, J. M. (2008). Association of Common C-Reactive Protein (CRP) Gene Polymorphisms With Baseline Plasma CRP Levels and Fenofibrate Response: The GOLDN Study. Diabetes Care 31: 910-915 [Abstract] [Full Text]  
• Mohler, E. R. III, Ballantyne, C. M., Davidson, M. H., Hanefeld, M., Ruilope, L. M., Johnson, J. L., Zalewski, A., for the Darapladib Investigators, (2008). The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients With Stable Coronary Heart Disease or Coronary Heart Disease Risk Equivalent: The Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. J Am Coll Cardiol 51: 1632-1641 [Abstract] [Full Text]  
• Danese, A., Moffitt, T. E., Pariante, C. M., Ambler, A., Poulton, R., Caspi, A. (2008). Elevated Inflammation Levels in Depressed Adults With a History of Childhood Maltreatment. Arch Gen Psychiatry 65: 409-415 [Abstract] [Full Text]  
• Weintraub, W. S., Diamond, G. A. (2008). Predicting Cardiovascular Events with Coronary Calcium Scoring. NEJM 358: 1394-1396 [Full Text]  
• Shirali, A. C., Bia, M. J. (2008). Management of Cardiovascular Disease in Renal Transplant Recipients. CJASN 3: 491-504 [Abstract] [Full Text]  
• Murphy, D. M., Forrest, I. A., Corris, P. A., Johnson, G. E., Small, T., Jones, D., Fisher, A. J., Egan, J. J., Cawston, T. E., Ward, C., Lordan, J. L. (2008). Simvastatin attenuates release of neutrophilic and remodeling factors from primary bronchial epithelial cells derived from stable lung transplant recipients. Am. J. Physiol. Lung Cell. Mol. Physiol. 294: L592-L599 [Abstract] [Full Text]  
• Nesto, R. W., Mackie, K. (2008). Endocannabinoid system and its implications for obesity and cardiometabolic risk. Eur Heart J Suppl 10: B34-B41 [Abstract] [Full Text]  
• Gill, J. S. (2008). Cardiovascular Disease in Transplant Recipients: Current and Future Treatment Strategies. CJASN 3: S29-S37 [Abstract] [Full Text]  
• Miller, M., Cannon, C. P., Murphy, S. A., Qin, J., Ray, K. K., Braunwald, E., for the PROVE IT-TIMI 22 Investigators, (2008). Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial.. J Am Coll Cardiol 51: 724-730 [Abstract] [Full Text]  
• Lee, S-S., Singh, S., Magder, L., Petri, M. (2008). Predictors of high sensitivity C-reactive protein levels in patients with systemic lupus erythematosus. Lupus 17: 114-123 [Abstract]  
• Berbee, J. F. P., Mooijaart, S. P., de Craen, A. J. M., Havekes, L. M., van Heemst, D., Rensen, P. C. N., Westendorp, R. G. J. (2008). Plasma Apolipoprotein CI Protects Against Mortality From Infection in Old Age. J. Gerontol. A Biol. Sci. Med. Sci. 63: 122-126 [Abstract] [Full Text]  
• Ridker, P. M (2008). High-Sensitivity C-Reactive Protein as a Predictor of All-Cause Mortality: Implications for Research and Patient Care. Clin. Chem. 54: 234-237 [Full Text]  
• Bedard, P. W., Clerin, V., Sushkova, N., Tchernychev, B., Antrilli, T., Resmini, C., Keith, J. C. Jr., Hennan, J. K., Kaila, N., DeBernardo, S., Janz, K., Wang, Q., Crandall, D. L., Schaub, R. G., Shaw, G. D., Carter, L. L. (2008). Characterization of the Novel P-Selectin Inhibitor PSI-697 [2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h] Quinoline-4-carboxylic acid] in Vitro and in Rodent Models of Vascular Inflammation and Thrombosis. J. Pharmacol. Exp. Ther. 324: 497-506 [Abstract] [Full Text]  
• Iakoubova, O. A., Sabatine, M. S., Rowland, C. M., Tong, C. H., Catanese, J. J., Ranade, K., Simonsen, K. L., Kirchgessner, T. G., Cannon, C. P., Devlin, J. J., Braunwald, E. (2008). Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study.. J Am Coll Cardiol 51: 449-455 [Abstract] [Full Text]  
• Kircher, M. F., Grimm, J., Swirski, F. K., Libby, P., Gerszten, R. E., Allport, J. R., Weissleder, R. (2008). Noninvasive In Vivo Imaging of Monocyte Trafficking to Atherosclerotic Lesions. Circulation 117: 388-395 [Abstract] [Full Text]  
• Packard, R. R. S., Libby, P. (2008). Inflammation in Atherosclerosis: From Vascular Biology to Biomarker Discovery and Risk Prediction. Clin. Chem. 54: 24-38 [Abstract] [Full Text]  
• Ardigo, D., Assimes, T. L., Fortmann, S. P., Go, A. S., Hlatky, M., Hytopoulos, E., Iribarren, C., Tsao, P. S., Tabibiazar, R., Quertermous, T., for the ADVANCE Investigators, (2007). Circulating chemokines accurately identify individuals with clinically significant atherosclerotic heart disease. Physiol. Genomics 31: 402-409 [Abstract] [Full Text]  
• Szwast, S. J., Hendrie, H. C., Lane, K. A., Gao, S., Taylor, S. E., Unverzagt, F., Murrell, J., Deeg, M., Ogunniyi, A., Farlow, M. R., Hall, K. S. (2007). Association of statin use with cognitive decline in elderly African Americans. Neurology 69: 1873-1880 [Abstract] [Full Text]  
• Devaraj, S., Tang, R., Adams-Huet, B., Harris, A., Seenivasan, T., de Lemos, J. A, Jialal, I. (2007). Effect of high-dose {alpha}-tocopherol supplementation on biomarkers of oxidative stress and inflammation and carotid atherosclerosis in patients with coronary artery disease. Am. J. Clin. Nutr. 86: 1392-1398 [Abstract] [Full Text]  
• Nylaende, M., Kroese, A.J., Morken, B., Stranden, E., Sandbaek, G., Lindahl, A.K., Arnesen, H., Seljeflot, I. (2007). Beneficial effects of 1-year optimal medical treatment with and without additional PTA on inflammatory markers of atherosclerosis in patients with PAD. Results from the Oslo Balloon Angioplasty versus Conservative Treatment (OBACT) study. Vasc Med 12: 275-283 [Abstract]  
• Gortney, J. S., Sanders, R. M. (2007). Impact of C-reactive protein on treatment of patients with cardiovascular disease. Am J Health Syst Pharm 64: 2009-2016 [Abstract] [Full Text]  
• Okura, H., Taguchi, H., Kubo, T., Toda, I., Yoshiyama, M., Yoshikawa, J., Yoshida, K. (2007). Impact of arterial remodelling and plaque rupture on target and non-target lesion revascularisation after stent implantation in patients with acute coronary syndrome: an intravascular ultrasound study. Heart 93: 1219-1225 [Abstract] [Full Text]  
• Memoli, B., Procino, A., Calabro, P., Esposito, P., Grandaliano, G., Pertosa, G., Prete, M. D., Andreucci, M., Lillo, S. D., Ferulano, G., Cillo, C., Savastano, S., Colao, A., Guida, B. (2007). Inflammation may modulate IL-6 and C-reactive protein gene expression in the adipose tissue: the role of IL-6 cell membrane receptor. Am. J. Physiol. Endocrinol. Metab. 293: E1030-E1035 [Abstract] [Full Text]  
• Scirica, B. M., Morrow, D. A., Cannon, C. P., de Lemos, J. A., Murphy, S., Sabatine, M. S., Wiviott, S. D., Rifai, N., McCabe, C. H., Braunwald, E., for the Thrombolysis in Myocardial Infarction (TIM, (2007). Clinical Application of C-Reactive Protein Across the Spectrum of Acute Coronary Syndromes. Clin. Chem. 53: 1800-1807 [Abstract] [Full Text]  
• Decensi, A., Gandini, S., Serrano, D., Cazzaniga, M., Pizzamiglio, M., Maffini, F., Pelosi, G., Daldoss, C., Omodei, U., Johansson, H., Macis, D., Lazzeroni, M., Penotti, M., Sironi, L., Moroni, S., Bianco, V., Rondanina, G., Gjerde, J., Guerrieri-Gonzaga, A., Bonanni, B. (2007). Randomized Dose-Ranging Trial of Tamoxifen at Low Doses in Hormone Replacement Therapy Users. JCO 25: 4201-4209 [Abstract] [Full Text]  
• Martin-Fuentes, P., Civeira, F., Recalde, D., Garcia-Otin, A. L., Jarauta, E., Marzo, I., Cenarro, A. (2007). Individual Variation of Scavenger Receptor Expression in Human Macrophages with Oxidized Low-Density Lipoprotein Is Associated with a Differential Inflammatory Response. J. Immunol. 179: 3242-3248 [Abstract] [Full Text]  
• Kalantar-Zadeh, K. (2007). Inflammatory Marker Mania in Chronic Kidney Disease: Pentraxins at the Crossroad of Universal Soldiers of Inflammation. CJASN 2: 872-875 [Full Text]  
• Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E. Jr, Chavey, W. E. II, Fesmire, F. M., Hochman, J. S., Levin, T. N., Lincoff, A. M., Peterson, E. D., Theroux, P., Wenger, N. K., Wright, R. S., Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Krumholz, H. M., Kushner, F. G., Lytle, B. W., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B. (2007). ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 50: e1-e157 [Full Text]  
• Momin, A., Melikian, N., Wheatcroft, S. B., Grieve, D., John, L. C., El Gamel, A., Marrinan, M. T., Desai, J. B., Driver, C., Sherwood, R., Shah, A. M., Kearney, M. T. (2007). The association between saphenous vein endothelial function, systemic inflammation, and statin therapy in patients undergoing coronary artery bypass surgery. J. Thorac. Cardiovasc. Surg. 134: 335-341 [Abstract] [Full Text]  
• Jialal, I., Miguelino, E., Griffen, S. C., Devaraj, S. (2007). Concomitant Reduction of Low-Density Lipoprotein-Cholesterol and Biomarkers of Inflammation with Low-Dose Simvastatin Therapy in Patients with Type 1 Diabetes. J. Clin. Endocrinol. Metab. 92: 3136-3140 [Abstract] [Full Text]  
• Afilalo, J., Majdan, A. A, Eisenberg, M. J (2007). Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. Heart 93: 914-921 [Abstract] [Full Text]  
• Yu, C.-M., Zhang, Q., Lam, L., Lin, H., Kong, S.-L., Chan, W., Fung, J. W.-H., Cheng, K. K K, Chan, I. H.-S., Lee, S. W.-L., Sanderson, J. E, Lam, C. W.-K. (2007). Comparison of intensive and low-dose atorvastatin therapy in the reduction of carotid intimal-medial thickness in patients with coronary heart disease. Heart 93: 933-939 [Abstract] [Full Text]  
• Packard, R. R. S., Schlegel, S., Senouf, D., Burger, F., Sigaud, P., Perneger, T., Siegrist, C.-A., Mach, F. (2007). Atorvastatin Treatment and Vaccination Efficacy. J Clin Pharmacol 47: 1022-1027 [Full Text]  
• Alsheikh-Ali, A. A., Maddukuri, P. V., Han, H., Karas, R. H. (2007). Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes, Rhabdomyolysis, and Cancer: Insights From Large Randomized Statin Trials. J Am Coll Cardiol 50: 409-418 [Abstract] [Full Text]  
• Authors/Task Force Members, , Bassand, J.-P., Hamm, C. W., Ardissino, D., Boersma, E., Budaj, A., Fernandez-Aviles, F., Fox, K. A.A., Hasdai, D., Ohman, E. M., Wallentin, L., Wijns, W., ESC Committee for Practice Guidelines (CPG), , Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Kristensen, S. D., Widimsky, P., McGregor, K., Sechtem, U., Tendera, M., Hellemans, I., Gomez, J. L. Z., Silber, S., Funck-Brentano, C., Document Reviewers, , Kristensen, S. D., Andreotti, F., Benzer, W., Bertrand, M., Betriu, A., De Caterina, R., DeSutter, J., Falk, V., Ortiz, A. F., Gitt, A., Hasin, Y., Huber, K., Kornowski, R., Lopez-Sendon, J., Morais, J., Nordrehaug, J. E., Silber, S., Steg, P. G., Thygesen, K., Tubaro, M., Turpie, A. G.G., Verheugt, F., Windecker, S. (2007). Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 28: 1598-1660 [Full Text]  
• Rohde, E., Bartmann, C., Schallmoser, K., Reinisch, A., Lanzer, G., Linkesch, W., Guelly, C., Strunk, D. (2007). Immune Cells Mimic the Morphology of Endothelial Progenitor Colonies In Vitro. Stem Cells 25: 1746-1752 [Abstract] [Full Text]  
• Ray, K. K., Morrow, D. A., Sabatine, M. S., Shui, A., Rifai, N., Cannon, C. P., Braunwald, E. (2007). Long-Term Prognostic Value of Neopterin: A Novel Marker of Monocyte Activation in Patients With Acute Coronary Syndrome. Circulation 115: 3071-3078 [Abstract] [Full Text]  
• Sethi, M., Collard, C. D. (2007). Perioperative Statin Therapy: Are Formal Guidelines and Physician Education Needed?. Anesth. Analg. 104: 1322-1324 [Full Text]  
• Le Manach, Y., Godet, G., Coriat, P., Martinon, C., Bertrand, M., Fleron, M.-H., Riou, B. (2007). The Impact of Postoperative Discontinuation or Continuation of Chronic Statin Therapy on Cardiac Outcome After Major Vascular Surgery. Anesth. Analg. 104: 1326-1333 [Abstract] [Full Text]  
• Ridker, P. M. (2007). C-Reactive Protein and the Prediction of Cardiovascular Events Among Those at Intermediate Risk: Moving an Inflammatory Hypothesis Toward Consensus. J Am Coll Cardiol 49: 2129-2138 [Abstract] [Full Text]  
• Tuzcu, E. M., Nicholls, S. J. (2007). Statins: Targeting Inflammation by Lowering Low-Density Lipoprotein?. J Am Coll Cardiol 49: 2010-2012 [Full Text]  
• Chang, J. D., Sukhova, G. K., Libby, P., Schvartz, E., Lichtenstein, A. H., Field, S. J., Kennedy, C., Madhavarapu, S., Luo, J., Wu, D., Cantley, L. C. (2007). Deletion of the phosphoinositide 3-kinase p110{gamma} gene attenuates murine atherosclerosis. Proc. Natl. Acad. Sci. USA 104: 8077-8082 [Abstract] [Full Text]  
• Gupta, R., Plantinga, L. C., Fink, N. E., Melamed, M. L., Coresh, J., Fox, C. S., Levin, N. W., Powe, N. R. (2007). Statin Use and Hospitalization for Sepsis in Patients With Chronic Kidney Disease. JAMA 297: 1455-1464 [Abstract] [Full Text]  
• Cannon, C. P., Braunwald, E. (2007). Reply. J Am Coll Cardiol 49: 1502-1503 [Full Text]  
• NACB WRITING GROUP MEMBERS, , Morrow, D. A., Cannon, C. P., Jesse, R. L., Newby, L. K., Ravkilde, J., Storrow, A. B., Wu, A. H.B., Christenson, R. H. (2007). National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes. Circulation 115: e356-e375 [Full Text]  
• Bisoendial, R. J., Kastelein, J. J. P., Peters, S. L. M., Levels, J. H. M., Birjmohun, R., Rotmans, J. I., Hartman, D., Meijers, J. C. M., Levi, M., Stroes, E. S. G. (2007). Effects of CRP infusion on endothelial function and coagulation in normocholesterolemic and hypercholesterolemic subjects. J. Lipid Res. 48: 952-960 [Abstract] [Full Text]  
• NACB WRITING GROUP MEMBERS, , Morrow, D. A., Cannon, C. P., Jesse, R. L., Newby, L. K., Ravkilde, J., Storrow, A. B., Wu, A. H.B., Christenson, R. H., NACB COMMITTEE MEMBERS, , Christenson, R. H., Apple, F. S., Cannon, C. P., Francis, G., Jesse, R. L., Morrow, D. A., Newby, L. K., Ravkilde, J., Storrow, A. B., Tang, W., Wu, A. H.B. (2007). National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes. Clin. Chem. 53: 552-574 [Full Text]  
• Baker, W. L, White, C M. (2007). Post-Cardiothoracic Surgery Atrial Fibrillation: A Review of Preventive Strategies. The Annals of Pharmacotherapy 41: 587-598 [Abstract] [Full Text]  
• Lip, G. Y.H., Patel, J. V., Hughes, E., Hart, R. G. (2007). High-Sensitivity C-Reactive Protein and Soluble CD40 Ligand as Indices of Inflammation and Platelet Activation in 880 Patients With Nonvalvular Atrial Fibrillation: Relationship to Stroke Risk Factors, Stroke Risk Stratification Schema, and Prognosis. Stroke 38: 1229-1237 [Abstract] [Full Text]  
• Sabatine, M. S., Morrow, D. A., Jablonski, K. A., Rice, M. M., Warnica, J. W., Domanski, M. J., Hsia, J., Gersh, B. J., Rifai, N., Ridker, P. M, Pfeffer, M. A., Braunwald, E., for the PEACE Investigators, (2007). Prognostic Significance of the Centers for Disease Control/American Heart Association High-Sensitivity C-Reactive Protein Cut Points for Cardiovascular and Other Outcomes in Patients With Stable Coronary Artery Disease. Circulation 115: 1528-1536 [Abstract] [Full Text]  
• Patel, T. N., Shishehbor, M. H., Bhatt, D. L. (2007). A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis. Eur Heart J 28: 664-672 [Abstract] [Full Text]  
• Revkin, J. H., Shear, C. L., Pouleur, H. G., Ryder, S. W., Orloff, D. G. (2007). Biomarkers in the Prevention and Treatment of Atherosclerosis: Need, Validation, and Future. Pharmacol. Rev. 59: 40-53 [Abstract] [Full Text]  
• Morrow, D. A., de Lemos, J. A. (2007). Benchmarks for the Assessment of Novel Cardiovascular Biomarkers. Circulation 115: 949-952 [Full Text]  
• Sattar, N., Murray, H. M., McConnachie, A., Blauw, G. J., Bollen, E. L.E.M., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., Kamper, A. M., Macfarlane, P. W., Murphy, M. B., Packard, C. J., Perry, I. J., Stott, D. J., Sweeney, B. J., Twomey, C., Westendorp, R. G.J., Shepherd, J., for the PROSPER Study Group, (2007). C-Reactive Protein and Prediction of Coronary Heart Disease and Global Vascular Events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation 115: 981-989 [Abstract] [Full Text]  
• Nicholls, S. J., Tuzcu, E. M., Sipahi, I., Grasso, A. W., Schoenhagen, P., Hu, T., Wolski, K., Crowe, T., Desai, M. Y., Hazen, S. L., Kapadia, S. R., Nissen, S. E. (2007). Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis. JAMA 297: 499-508 [Abstract] [Full Text]  
• Szeto, C.-C., Chow, K.-M., Lam, C. W.-K., Leung, C.-B., Kwan, B. C.-H., Chung, K.-Y., Law, M.-C., Li, P. K.-T. (2007). Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--A 1-year randomized control trial. Nephrol Dial Transplant 22: 552-559 [Abstract] [Full Text]  
• Rocker, C., Manolov, D. E., Kuzmenkina, E. V., Tron, K., Slatosch, H., Torzewski, J., Nienhaus, G. U. (2007). Affinity of C-Reactive Protein toward Fc{gamma}RI Is Strongly Enhanced by the {gamma}-Chain. Am. J. Pathol. 170: 755-763 [Abstract] [Full Text]  
• Belay, B., Belamarich, P. F., Tom-Revzon, C. (2007). The Use of Statins in Pediatrics: Knowledge Base, Limitations, and Future Directions. Pediatrics 119: 370-380 [Abstract] [Full Text]  
• Anwaruddin, S., Askari, A. T., Topol, E. J. (2007). Redefining Risk in Acute Coronary Syndromes Using Molecular Medicine. J Am Coll Cardiol 49: 279-289 [Abstract] [Full Text]  
• Hanefeld, M., Marx, N., Pfutzner, A., Baurecht, W., Lubben, G., Karagiannis, E., Stier, U., Forst, T. (2007). Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity C-Reactive Protein: The PIOSTAT Study. J Am Coll Cardiol 49: 290-297 [Abstract] [Full Text]  
• Klein, L. W. (2007). Atherosclerosis Regression, Vascular Remodeling, and Plaque Stabilization. J Am Coll Cardiol 49: 271-273 [Full Text]  
• Liuzzo, G., Santamaria, M., Biasucci, L. M., Narducci, M., Colafrancesco, V., Porto, A., Brugaletta, S., Pinnelli, M., Rizzello, V., Maseri, A., Crea, F. (2007). Persistent Activation of Nuclear Factor Kappa-B Signaling Pathway in Patients With Unstable Angina and Elevated Levels of C-Reactive Protein: Evidence for a Direct Proinflammatory Effect of Azide and Lipopolysaccharide-Free C-Reactive Protein on Human Monocytes Via Nuclear Factor Kappa-B Activation. J Am Coll Cardiol 49: 185-194 [Abstract] [Full Text]  
• Jialal, I., Devaraj, S. (2007). The Role of C-Reactive Protein Activation of Nuclear Factor Kappa-B in the Pathogenesis of Unstable Angina. J Am Coll Cardiol 49: 195-197 [Full Text]  
• Capuzzi, D. M., Freeman, J. S. (2007). C-Reactive Protein and Cardiovascular Risk in the Metabolic Syndrome and Type 2 Diabetes: Controversy and Challenge. Clin. Diabetes 25: 16-22 [Abstract] [Full Text]  
• Blanco-Colio, L. M., Martin-Ventura, J. L., de Teresa, E., Farsang, C., Gaw, A., Gensini, G., Leiter, L. A., Langer, A., Martineau, P., Hernandez, G., Egido, J., on behalf of the ACTFAST investigators, (2007). Increased Soluble Fas Plasma Levels in Subjects at High Cardiovascular Risk: Atorvastatin on Inflammatory Markers (AIM) Study, a Substudy of ACTFAST. Arterioscler. Thromb. Vasc. Bio. 27: 168-174 [Abstract] [Full Text]  
• Tsimikas, S., Aikawa, M., Miller, F. J. Jr, Miller, E. R., Torzewski, M., Lentz, S. R., Bergmark, C., Heistad, D. D., Libby, P., Witztum, J. L. (2007). Increased Plasma Oxidized Phospholipid:Apolipoprotein B-100 Ratio With Concomitant Depletion of Oxidized Phospholipids From Atherosclerotic Lesions After Dietary Lipid-Lowering: A Potential Biomarker of Early Atherosclerosis Regression. Arterioscler. Thromb. Vasc. Bio. 27: 175-181 [Abstract] [Full Text]  
• Crawford, D. C., Sanders, C. L., Qin, X., Smith, J. D., Shephard, C., Wong, M., Witrak, L., Rieder, M. J., Nickerson, D. A. (2006). Genetic Variation Is Associated With C-Reactive Protein Levels in the Third National Health and Nutrition Examination Survey. Circulation 114: 2458-2465 [Abstract] [Full Text]  
• Sinning, J.-M., Bickel, C., Messow, C.-M., Schnabel, R., Lubos, E., Rupprecht, H. J., Espinola-Klein, C., Lackner, K. J., Tiret, L., Munzel, T., Blankenberg, S., for the Athero Gene Investigators, (2006). Impact of C-reactive protein and fibrinogen on cardiovascular prognosis in patients with stable angina pectoris: the AtheroGene study. Eur Heart J 27: 2962-2968 [Abstract] [Full Text]  
• Save, V., Patil, N., Moulik, N., Rajadhyaksha, G. (2006). Effect of Atorvastatin on Type 2 Diabetic Dyslipidemia. J CARDIOVASC PHARMACOL THER 11: 262-270 [Abstract]  
• Persson, F., Rossing, P., Hovind, P., Stehouwer, C. D.A., Schalkwijk, C., Tarnow, L., Parving, H.-H. (2006). Irbesartan Treatment Reduces Biomarkers of Inflammatory Activity in Patients With Type 2 Diabetes and Microalbuminuria: An IRMA 2 Substudy. Diabetes 55: 3550-3555 [Abstract] [Full Text]  
• Van de Veire, N R, Philippe, J, De Winter, O, Langlois, M, Bernard, D, De Sutter, J (2006). Neurohumoral and inflammatory activation in patients with coronary artery disease treated with statins.. Heart 92: 1858-1859 [Full Text]  
• Goicoechea, M., de Vinuesa, S. G., Lahera, V., Cachofeiro, V., Gomez-Campdera, F., Vega, A., Abad, S., Luno, J. (2006). Effects of Atorvastatin on Inflammatory and Fibrinolytic Parameters in Patients with Chronic Kidney Disease. J. Am. Soc. Nephrol. 17: S231-S235 [Abstract] [Full Text]  
• Waxman, S., Ishibashi, F., Muller, J. E. (2006). Detection and Treatment of Vulnerable Plaques and Vulnerable Patients: Novel Approaches to Prevention of Coronary Events. Circulation 114: 2390-2411 [Full Text]  
• Johnson, R. C., Leopold, J. A., Loscalzo, J. (2006). Vascular Calcification: Pathobiological Mechanisms and Clinical Implications.. Circ. Res. 99: 1044-1059 [Abstract] [Full Text]  
• Daneshtalab, N., Lewanczuk, R. Z., Russell, A. S., Jamali, F. (2006). Drug-disease interactions: losartan effect is not downregulated by rheumatoid arthritis.. J Clin Pharmacol 46: 1344-1355 [Abstract] [Full Text]  
• Libby, P., Ridker, P. M. (2006). Inflammation and Atherothrombosis: From Population Biology and Bench Research to Clinical Practice. J Am Coll Cardiol 48: A33-A46 [Abstract] [Full Text]  
• Elkind, M. S. V., Tai, W., Coates, K., Paik, M. C., Sacco, R. L. (2006). High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke.. Arch Intern Med 166: 2073-2080 [Abstract] [Full Text]  
• Blankenberg, S., Yusuf, S. (2006). The inflammatory hypothesis: any progress in risk stratification and therapeutic targets?. Circulation 114: 1557-1560 [Full Text]  
• Bos, M. J., Schipper, C. M. A., Koudstaal, P. J., Witteman, J. C.M., Hofman, A., Breteler, M. M.B. (2006). High Serum C-Reactive Protein Level Is Not an Independent Predictor for Stroke: The Rotterdam Study. Circulation 114: 1591-1598 [Abstract] [Full Text]  
• Hayward, R. A., Hofer, T. P., Vijan, S. (2006). Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem.. ANN INTERN MED 145: 520-530 [Abstract] [Full Text]